Liver cancer: Effect of HCV clearance with direct-acting antiviral agents on HCC

Nature Reviews Gastroenterology and Hepatology

Volumn 13, Issue 10, 2016, Pages 561-562

  Llovet, Josep M ^a,b,c   Villanueva, Augusto ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRAL AGENT; INTERFERON; UNCLASSIFIED DRUG;

CANCER INCIDENCE; CANCER RECURRENCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOMODULATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SHORT SURVEY; TREATMENT RESPONSE; TUMOR ABLATION; VIRAL CLEARANCE; LIVER TUMOR;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS C; HUMANS; LIVER NEOPLASMS;

EID: 84984815857     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2016.140     Document Type: Short Survey

References (10)

1. Conti, F. et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct acting antivirals. J. Hepatol. http:// dx.doi.org/10.1016/j.jhep.2016.06.015 (2016).
2. Cheung, M. C. M. et al. Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J. Hepatol. http://dx.doi.org/10.1016/j.jhep.2016.06.019 (2016).
3. Reig, M. et al. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J. Hepatol. http://dx.doi.org/10.1016/ j.jhep.2016.04.008 (2016).
4. Yang, J. D. et al. Direct acting antiviral therapy and tumor recurrence after liver transplant for hepatitis C-associated hepatocellular carcinoma. J. Hepatol. http://dx.doi.org/10.1016/j.jhep.2016.06.02 (2016).
5. The ANRS collaborative study group on hepatocellular carcinoma. Lack of evidence of an effect of direct acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J. Hepatol. http://dx.doi.org/10.1016/j.jhep.2016.05.045 (2016).
6. Morgan, R. L. et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann. Intern. Med. 158, 329-337 (2013).
7. Lok, A. S. et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136, 138-148 (2009).
8. European Association For The Study Of The Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908-943 (2012).
9. Bruix, J. et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 16, 1344-1354 (2015).
10. Serti, E. et al. Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. Gastroenterology 149, 190-200 (2015).